Navigation Links
Androgen Production Continues in Prostate Cancer Tumors
Date:6/3/2008

Growths are able to maintain significant testosterone levels despite therapy, study finds

TUESDAY, June 3 (HealthDay News) -- U.S. researchers have uncovered new information about how metastatic prostate cancer becomes resistant to androgen-deprivation therapy, which suppresses circulating testosterone, the hormone that promotes prostate cancer growth.

Androgen therapy, which involves the use of surgical castration or medical castration with testosterone-blocking drugs, does extend survival time for patients, but it isn't a cure. Eventually, the cancer becomes resistant to androgen deprivation and continues to grow.

"We found that despite the suppression of circulating androgen levels to very low or castrate levels, metastatic prostate tumors are themselves able to maintain significant levels of testosterone, which fuels the growth of the cancer," Dr. Elahe Mostaghel, a clinical research association at Seattle's Fred Hutchinson Cancer Research Center, said in a prepared statement.

Mostaghel and colleagues found that testosterone levels in metastatic prostate tumors (cancer that's spread from the prostate to other parts of the body) from castrate men who'd just died were four times higher than in benign and cancerous prostate tissue in men with normal circulating androgen levels.

They also discovered that metastatic prostate tumor tissue contains the genetic information needed to make the proteins that produce testosterone and other androgen hormones.

"We not only found that metastatic tumor tissues have high enough androgen levels within them to support continued growth of the tumor cells, but also a critically important reason behind why those androgens are there -- the discovery that the gene pathways for synthesizing androgens from cholesterol appear to be present in the distant tumor sites. This finding will allow us to start honing in on the specific source of those androgens and how we can eliminate them," Mostaghel said.

"As we develop new drug targets, we will need to focus on enzymes that seem to be active in the tumor itself. This offers a new way of looking at hormone suppression. In addition to systemic suppression, it suggests we also need to target hormone suppression much more specifically, inside the tumor itself."

The study was published in the June 1 issue of Cancer Research.

More information

The National Cancer Institute has more about prostate cancer treatment.



-- Robert Preidt



SOURCE: Fred Hutchinson Cancer Research Center, news release, June 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. How advanced prostate cancer becomes resistant to androgen-deprivation therapy
2. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
3. Golden Rainbow Takes a Musical Journey for Its 22nd Annual Ribbon of Life Production Show
4. JMR Electronics BlueStor(TM) Storage Array Empowers HoneySheds Post Production Process
5. Dutch Authorize Manufacture of Vaccinogens New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
6. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
7. Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline
8. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
9. Disturbed regulation of insulin production
10. European Society of Human Reproduction & Embryology 24th annual meeting
11. Worlds Lightest, Rigid, Folding Frame Wheelchair now in Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... CO (PRWEB) , ... June 20, 2017 , ... ... a report contending that the introduction of school choice can promote economic development ... a charter school that has, according to the report, contributed to the economic ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider ... the clinical trials market. Similar to its approach in demonstrating positive outcomes in the ... marketplace by proving the value of eVisits to support virtual studies. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn ... with the VATECH PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, ... place dental implants precisely and restore oral health for those who are missing ...
(Date:6/20/2017)... , ... June 20, 2017 , ... As a leading ... the link between stroke and gum disease. Those with bleeding gums in Vancouver, BC, ... untreated, this condition can lead to heart disease, stroke and diabetes. Drs. Parviz Roshan, ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with advanced capabilities ... scanner provides higher-resolution images than traditional MRIs, enabling doctors to get a more ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/12/2017)... Inc., a biotechnology company focused on the development of novel ... and Head of Virology Kristin Bedard has been invited to ... Beyond meeting sponsored by Life Science Washington.  This Symposium ... PDT at the Agora Conference Center in Seattle, ... joined by other leaders in infectious disease research and the ...
Breaking Medicine Technology: